Moderna said it continues to target 10% revenue growth this year, as the company’s fourth-quarter loss narrowed from a year ...

By Mariam Sunny and Michael Erman Feb 13 (Reuters) - Moderna said it is looking for growth overseas after the U.S. FDA ...

Feb 13 (Reuters) - Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, helped by sales of its ...

Moderna will report its fourth-quarter 2025 earnings this morning in an investor call that’s taken on even more interest in ...

The head of the agency’s vaccine division, Vinay Prasad, has overruled pushback from career staffers.

Moderna received a refusal-to-file letter from the FDA objecting to how it conducted a 40,000-person trial comparing its new ...

By Sneha S K Feb 10 (Reuters) - The U.S. Food and Drug Administration will not review Moderna's approval application for its ...

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story FDA refuses ...

The flu vaccine is its first using mRNA technology for influenza.

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)Reports ...

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ...

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...